Premium
Frequency of MYD88 and CD79B mutations, and MGMT methylation in primary central nervous system diffuse large B ‐cell lymphoma
Author(s) -
Zheng Mei,
Perry Anamarija M.,
Bierman Philip,
Loberiza Fausto,
Nasr Michel R.,
Szwajcer David,
Del Bigio Marc R.,
Smith Lynette M.,
Zhang Weiwei,
Greiner Timothy C.
Publication year - 2017
Publication title -
neuropathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.701
H-Index - 61
eISSN - 1440-1789
pISSN - 0919-6544
DOI - 10.1111/neup.12405
Subject(s) - diffuse large b cell lymphoma , cancer research , lymphoma , methylation , o 6 methylguanine dna methyltransferase , mutation , methyltransferase , biology , medicine , primary central nervous system lymphoma , oncology , gene , genetics
Primary CNS diffuse large B ‐cell lymphoma ( PCNS ‐ DLBCL ) and systemic DLBCL harbor mutations in MYD88 and CD79B . DNA methyltransferase ( MGMT ) is methylated in some DLBCL . Our goal was to investigate the frequencies of these events, which have not been previously reported within the same series of patients with PCNS ‐ DLBCL . Fifty‐four cases of PCNS‐DLBCL from two institutions were analyzed by S anger sequencing for MYD88 and CD79B , and pyrosequencing for MGMT . MYD88 mutations were identified in 68.8% (35 of 51 cases), with L 265 P being the most frequent mutation. Mutations other than L 265 P were identified in 21.6% of cases, of which eight novel MYD88 mutations were identified. Of mutated cases, 17.6% had homozygous/hemizygous MYD88 mutations, which has not been previously reported in PCNS ‐ DLBCL . CD79B mutations were found in six of 19 cases (31.6%), all in the Y 196 mutation hotspot. MGMT methylation was observed in 37% (20 of 54 cases). There was no significant difference in median overall survival ( OS ) between the wild type and mutated MYD88 cases, or between methylated and unmethylated MGMT cases. However, a significant difference ( P = 0.028) was noted in median OS between the wild type and mutated CD79B cases.